MX2021008172A - Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso. - Google Patents

Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.

Info

Publication number
MX2021008172A
MX2021008172A MX2021008172A MX2021008172A MX2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A
Authority
MX
Mexico
Prior art keywords
subject
adenosine receptor
loss effect
achieving
fat loss
Prior art date
Application number
MX2021008172A
Other languages
English (en)
Spanish (es)
Inventor
Pnina Fishman
Shira Cohen
Motti Farbstein
Inbal Itzhak
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2021008172A publication Critical patent/MX2021008172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021008172A 2019-01-06 2020-01-05 Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso. MX2021008172A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes
PCT/IL2020/050011 WO2020141535A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect

Publications (1)

Publication Number Publication Date
MX2021008172A true MX2021008172A (es) 2021-08-11

Family

ID=65656120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008172A MX2021008172A (es) 2019-01-06 2020-01-05 Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.

Country Status (11)

Country Link
US (1) US12213990B2 (https=)
EP (1) EP3906034A1 (https=)
JP (3) JP2022517753A (https=)
KR (1) KR20210113279A (https=)
CN (1) CN113543790A (https=)
AU (1) AU2020205042B2 (https=)
BR (1) BR112021013084A2 (https=)
CA (1) CA3126002A1 (https=)
IL (2) IL264112A (https=)
MX (1) MX2021008172A (https=)
WO (1) WO2020141535A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300014340A1 (it) * 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1997027173A2 (en) 1996-01-24 1997-07-31 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
JP2003517423A (ja) 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1983990B1 (en) 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
US20130324461A1 (en) * 2010-08-26 2013-12-05 Michail V. Sitkovsky Methods and compositions for preventing or treating obesity
JP2015504088A (ja) 2012-01-23 2015-02-05 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 肝疾患の治療
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
CN113543790A (zh) 2021-10-22
AU2020205042B2 (en) 2024-10-10
IL284463B1 (en) 2026-04-01
IL264112A (en) 2020-07-30
BR112021013084A2 (pt) 2021-09-21
WO2020141535A1 (en) 2020-07-09
JP2022517753A (ja) 2022-03-10
AU2020205042A1 (en) 2021-07-15
US20220079968A1 (en) 2022-03-17
EP3906034A1 (en) 2021-11-10
JP2025098147A (ja) 2025-07-01
IL284463A (en) 2021-08-31
KR20210113279A (ko) 2021-09-15
JP2023100928A (ja) 2023-07-19
US12213990B2 (en) 2025-02-04
CA3126002A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
PH12020551251A1 (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
ES2692773T3 (es) Tratamientos para la fibrosis
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
MX2025006615A (es) Metodos para alterar la composicion corporal
BR112022010061A2 (pt) Mistura de olhs para melhorar a microbiota das mulheres grávidas
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EA201792447A1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2017006639A (es) Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
CL2020000170A1 (es) Composición para su uso en la prevención y el tratamiento de patologías del aparato cardiovascular.
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
MX2021008172A (es) Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
MX2018006026A (es) Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.
BR112021024291A2 (pt) Composições e métodos que usam trigonelina e minerais para prevenção ou tratamento de condições ou distúrbios no músculo esquelético
BR112017014928A2 (pt) dispositivo de suporte lombar, kit, e método para prevenir ou tratar dor nas costas em uma pessoa
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CO2023009085A2 (es) Pauta posológica de levodopa
MY200894A (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
CL2020000207A1 (es) Agonistas del receptor de prostaciclina para la reducción de la grasa corporal.
ZA202201222B (en) Triazolo-pyrimidine compounds and uses thereof
佟强 Apathy and neuropsychological characteristics of newly diagnosed Parkinson's disease patients